Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Perrigo Co considers Tysabri rights sale

Thursday, November 10, 2016 9:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Drug group Perrigo Company (NYSE:PRGO) is to consider the strategic options for its royalty stream from multiple sclerosis drug Tysabri after pressure from activist investor Starboard Value.

The investor wants Perrigo to sell its Tysabri rights and this option will now be considered alongside a strategic review of all of its products.

Ireland-based Perrigo posted a net loss of $1.26bn, or $8.76 a share in its third quarter after impairment charges of almost US$1.7bn.

Stripping out the one-offs there was a profit per share US$1.65 per share, down from $1.76 last year.

Revenue rose slightly to $1.35bn.

Most of the impairments related to 2015’s acquisition of US$4.5bn purchase of Omega Pharma, where Perrigo expects to start legal action against the vendors.

Perrigo shareholders rejected a US$26bn takeover bid from rival pharma Mylan this time last year since when the share price has almost halved.

Today the shares were up 4% at US$87 valuing the group at just under US$12bn.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.